What to Expect from Mounjaro — a Realistic, Evidence-Based Picture

What the trial data actually showed, and why individual results vary

The SURMOUNT-1 results, published in the New England Journal of Medicine, followed 2,539 adults with obesity over 72 weeks. At 15mg, average body-weight reduction was around 20–21%. At 10mg it was around 19%, and at 5mg around 16%. Those numbers come from people taking the medicine alongside a reduced-calorie diet and increased physical activity, which the UK licence requires, so the injection alone is not the whole picture.

One misconception worth addressing gently: many people arrive expecting a steady, week-on-week drop from the start. In reality, the first few weeks are mostly about your body adjusting to the medicine. Significant fat loss accumulates over months, not days. The dose-titration schedule exists partly to let your system settle, so the 2.5mg starting pen is doing its job even when the scales barely move.

Individual variation is real. Genetics, starting weight, diet quality, activity levels and whether a weight-related condition is present all shape outcomes. The trial averages are the best available guide, not a personal forecast. For a fuller picture of the tirzepatide evidence base, the tirzepatide results overview covers the SURMOUNT programme in more detail.

The first four weeks: what most people actually notice

Appetite is usually the first thing to change. Tirzepatide acts on two gut-hormone receptors (GIP and GLP-1) that are involved in signalling fullness, slowing how quickly the stomach empties and reducing the drive to eat between meals. Many people find they feel satisfied much sooner than usual and that food simply occupies less mental space. That shift can happen within the first week for some; for others it is more gradual.

Side effects in this early period are almost always gastrointestinal: nausea is the most commonly reported, followed by constipation, loose stools, indigestion or reflux, and occasional burping. These tend to peak in the first few days after a new dose and ease as your system adjusts, usually within a week or two. Eating smaller portions, avoiding rich or fatty food around injection day, and staying well hydrated all help. If symptoms are severe or persistent, that is a conversation for your prescriber, not something to manage alone. The first-week guide has more detail on what is normal and what warrants a call.

Weight change in week one to four is modest for most people, often two to four pounds, sometimes less. That is not a sign the medicine is not working. The NHS notes that tirzepatide takes time to build its effect, and the 2.5mg starting dose is not the therapeutic level at which most people achieve their results.

Months two to six: when results become visible

After the first dose increase (usually at week four or five) appetite suppression typically deepens and weight loss becomes more consistent. This is the phase where most people begin to notice changes in how clothes fit and energy levels improve alongside the scale movement, and our Mounjaro guide covering what to expect walks through these changes in detail. The pattern in the trial data shows the steepest rate of loss in roughly months two through six, before the curve gradually flattens as the body settles at a lower weight.

Dose titration continues under prescriber review throughout this period. Not everyone reaches 15mg; the right dose is the highest that is well tolerated and producing a clinical response, that judgement belongs to your prescriber. If you are thinking about the cost of treatment over this period, the Mounjaro price guide covers what private treatment typically costs and what a legitimate quote includes.

By six months, NICE guidance notes that if less than 5% body weight has been lost at the highest tolerated dose, continuing is subject to clinical review. That threshold is a checkpoint, not a failure, it is the same evidence-based bar the NHS uses to assess ongoing benefit. Details of how NICE recommends tirzepatide are published on NICE TA1026.

Longer term: maintenance, dose and what happens if you stop

The 72-week SURMOUNT-1 data covers just under a year and a half. Weight loss continues beyond six months for most participants, with the largest reductions at the highest doses appearing at around 52–72 weeks. Weight is then broadly maintained while the medicine continues. Trials of GLP-1 and dual-agonist medicines consistently show that stopping treatment leads to gradual weight regain, a pattern that reflects how these medicines work (modifying appetite biology, not permanently altering it) rather than any failure of willpower.

That practical reality is worth knowing before you start. Many people use Mounjaro as part of a longer-term strategy: building dietary habits, increasing physical activity and addressing any underlying health conditions in parallel with treatment. Our prescribers review repeat orders before every dispatch, so there is ongoing clinical oversight throughout, not just at the start. If you have questions about how treatment is managed over time, the timeline guide and our FAQs address the most common ones.

Mounjaro is not licensed for use under 18, during pregnancy, or while breastfeeding or trying to conceive. Women using oral contraceptives should add a non-oral method for the first four weeks of treatment and for four weeks after each dose increase, as pill absorption may be reduced, your prescriber will cover this at consultation. If you are curious about the early experience before committing, our page on what to expect on week 2 of Mounjaro gives a clear picture of what that stage typically looks like. If you are considering starting treatment, speak to our prescribers for a same-day clinical review.